# PLCB2

## Overview
Phospholipase C beta 2 (PLCB2) is a gene that encodes the enzyme phospholipase C β2, which is a critical component of intracellular signal transduction pathways. This enzyme belongs to the phospholipase family and is primarily involved in the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) to generate inositol trisphosphate (IP3) and diacylglycerol (DAG), both of which act as secondary messengers in various cellular processes (Coburn1997Smooth). The protein is activated by G-protein subunits, particularly the Gβγ dimers, and interacts with small GTPases such as Rac, facilitating its recruitment to the plasma membrane and subsequent activation (Gresset2012The). PLCB2 plays a significant role in mediating physiological responses to extracellular stimuli, including neurotransmitters and hormones, and is involved in diverse cellular functions such as muscle contraction, endothelial cell signaling, and immune cell activation (Lo2014Neuropeptide; Block2016Gnb). The gene's expression and mutations have been linked to various clinical conditions, including congenital heart disease and hepatocellular carcinoma, highlighting its importance in both normal physiology and disease states (Izarzugaza2020Systems; Wang2019Diagnostic).

## Structure
Phospholipase C beta 2 (PLCB2) is characterized by several distinct structural features that contribute to its function in signal transduction. The protein includes a long carboxyl-terminal region downstream of the Y catalytic domain, which is crucial for its activation by G protein alpha subunits (αq) (Lee1993Activation). Between the X and Y catalytic domains, there is a region rich in acidic amino acids, which is a notable structural characteristic of PLC-β2 isozymes (Lee1993Activation).

PLCB2 is also known to undergo post-translational modifications, such as phosphorylation, which can influence its activity and interactions. The enzyme is activated by heterotrimeric G proteins, with different subunits modulating its activity. Specifically, the αq subunit and the beta-gamma (βγ) subunits interact with different regions of the enzyme, allowing for concurrent modulation by these subunits (Lee1993Activation).

In terms of isoforms, PLCB2 can exist in different forms due to splice variants, which may result in isoforms with distinct functions. These structural and functional variations are essential for the diverse roles of PLCB2 in cellular signaling pathways (Labelle1996Phospholipase).

## Function
Phospholipase C beta 2 (PLCB2) is an enzyme that plays a critical role in intracellular signal transduction by hydrolyzing phosphatidylinositol 4,5-bisphosphate (PIP2) to generate inositol trisphosphate (IP3) and diacylglycerol (DAG), which serve as secondary messengers in various signaling pathways. In smooth muscle cells, PLCB2 is associated with the sarcolemma and translocates from the cytosol to the sarcolemma upon stimulation with agonists like carbamylcholine, indicating its involvement in sarcolemma-associated signaling pathways and muscle contraction (Coburn1997Smooth).

PLCB2 is activated by G-protein subunits, particularly Gβγ, and interacts with small GTPases such as Rac, which facilitates its recruitment to the plasma membrane and subsequent activation (Gresset2012The). This enzyme is crucial for mediating physiological responses to extracellular stimuli, including neurotransmitters and hormones, through receptor-promoted activation (Gresset2012The).

In endothelial cells, PLCB2 is involved in the phosphoinositide signal transduction pathway, which regulates cellular processes such as gene expression, calcium release, and protein kinase activation. Neuropeptide Y (NPY) has been shown to downregulate PLCB2 expression in these cells, suggesting a regulatory mechanism that influences endothelial cell responses to stimuli (Lo2014Neuropeptide).

## Clinical Significance
Mutations and alterations in the expression of the PLCB2 gene have been implicated in several diseases and conditions. In the context of congenital heart disease (CHD), studies have identified a significant enrichment of pathogenic mutations in calcium-signaling genes, including PLCB2, among CHD cases. These mutations are associated with abnormal heart morphology and laterality defects, as demonstrated in zebrafish models where knockdown of the PLCB2 orthologue resulted in cardiac malformations (Izarzugaza2020Systems; Izarzugaza2019Systems). The research suggests that PLCB2 mutations may play a critical role in heart development and the etiology of CHD (Izarzugaza2020Systems).

In hepatocellular carcinoma (HCC) associated with hepatitis B virus, PLCB2 has been studied for its diagnostic value. Although PLCB2 shows lower expression in tumor tissues compared to normal tissues, it has been identified as a potential diagnostic marker for HCC. However, its role in prognosis is not significant, as it does not show a strong association with overall survival or recurrence-free survival in HCC patients (Wang2019Diagnostic). These findings highlight the complex role of PLCB2 in various diseases, emphasizing its potential clinical significance.

## Interactions
PLCB2 (phospholipase C beta 2) is involved in several protein interactions that are crucial for its role in intracellular signaling pathways. It interacts with G-protein subunits, particularly Gβγ dimers, which activate PLCB2 and mediate signal cascades (Lo2014Neuropeptide). This interaction is significant in the context of endothelial cells, where PLCB2 expression is modulated by Neuropeptide Y, affecting the PI signal transduction pathway (Lo2014Neuropeptide).

PLCB2 also interacts with Rac1, a small GTPase, forming a complex that is essential for the activation of LFA-1, a process crucial for neutrophil recruitment during inflammation (Block2016Gnb). This interaction is enhanced upon chemokine stimulation, such as with CXCL1, and is necessary for downstream signaling events, including the generation of inositol triphosphate (IP3) and calcium flux, which are critical for integrin activation and leukocyte adhesion (Block2016Gnb).

In melanoma cells, PLCB2 interacts with components of the Ras/Raf/MAPK signaling pathway. Silencing PLCB2 reduces the protein levels of Ras and Raf and decreases the phosphorylation of ERK1/2, indicating its role in influencing cell survival and apoptosis (Zhang2019Knockdown). These interactions highlight the multifaceted role of PLCB2 in various cellular processes and signaling pathways.


## References


[1. (Lee1993Activation) S B Lee, S H Shin, J R Hepler, A G Gilman, and S G Rhee. Activation of phospholipase c-beta 2 mutants by g protein alpha q and beta gamma subunits. Journal of Biological Chemistry, 268(34):25952–25957, December 1993. URL: http://dx.doi.org/10.1016/s0021-9258(19)74479-2, doi:10.1016/s0021-9258(19)74479-2. This article has 104 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/s0021-9258(19)74479-2)

[2. (Gresset2012The) Aurelie Gresset, John Sondek, and T. Kendall Harden. The Phospholipase C Isozymes and Their Regulation, pages 61–94. Springer Netherlands, 2012. URL: http://dx.doi.org/10.1007/978-94-007-3012-0_3, doi:10.1007/978-94-007-3012-0_3. This article has 146 citations.](https://doi.org/10.1007/978-94-007-3012-0_3)

[3. (Labelle1996Phospholipase) Edward F. Labelle and Erzsébet Polyák. Phospholipase c β2 in vascular smooth muscle. Journal of Cellular Physiology, 169(2):358–363, November 1996. URL: http://dx.doi.org/10.1002/(SICI)1097-4652(199611)169:2<358::AID-JCP15>3.0.CO;2-5, doi:10.1002/(sici)1097-4652(199611)169:2<358::aid-jcp15>3.0.co;2-5. This article has 36 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/(SICI)1097-4652(199611)169:2)

[4. (Zhang2019Knockdown) Huahui Zhang, Tao Xie, Yongjie Shui, and Yiying Qi. Knockdown of plcb2 expression reduces melanoma cell viability and promotes melanoma cell apoptosis by altering ras/raf/mapk signals. Molecular Medicine Reports, November 2019. URL: http://dx.doi.org/10.3892/mmr.2019.10798, doi:10.3892/mmr.2019.10798. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/mmr.2019.10798)

[5. (Block2016Gnb) Helena Block, Anika Stadtmann, Daniel Riad, Jan Rossaint, Charlotte Sohlbach, Giulia Germena, Dianqing Wu, Scott I. Simon, Klaus Ley, and Alexander Zarbock. Gnb isoforms control a signaling pathway comprising rac1, plcβ2, and plcβ3 leading to lfa-1 activation and neutrophil arrest in vivo. Blood, 127(3):314–324, January 2016. URL: http://dx.doi.org/10.1182/blood-2015-06-651034, doi:10.1182/blood-2015-06-651034. This article has 32 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1182/blood-2015-06-651034)

[6. (Wang2019Diagnostic) Xiangkun Wang, Ketuan Huang, Xianmin Zeng, Zhengqian Liu, Xiwen Liao, Chengkun Yang, Tingdong Yu, Chuangye Han, Guangzhi Zhu, Wei Qin, and Tao Peng. Diagnostic and prognostic value of mrna expression of phospholipase c β family genes in hepatitis b virus‑associated hepatocellular carcinoma. Oncology Reports, March 2019. URL: http://dx.doi.org/10.3892/or.2019.7066, doi:10.3892/or.2019.7066. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/or.2019.7066)

7. (Izarzugaza2019Systems) Systems genetics analysis identify calcium signalling defects as novel cause of congenital heart disease. This article has 1 citations.

[8. (Izarzugaza2020Systems) Jose M. G. Izarzugaza, Sabrina G. Ellesøe, Canan Doganli, Natasja Spring Ehlers, Marlene D. Dalgaard, Enrique Audain, Gregor Dombrowsky, Karina Banasik, Alejandro Sifrim, Anna Wilsdon, Bernard Thienpont, Jeroen Breckpot, Marc Gewillig, Hashim Abdul-Khaliq, Hans-Heiner Kramer, Felix Berger, Brigitte Stiller, Ulrike Bauer, Thomas Pickardt, Sabine Klaassen, J. David Brook, Marc-Phillip Hitz, Lars A. Larsen, and Søren Brunak. Systems genetics analysis identifies calcium-signaling defects as novel cause of congenital heart disease. Genome Medicine, August 2020. URL: http://dx.doi.org/10.1186/s13073-020-00772-z, doi:10.1186/s13073-020-00772-z. This article has 18 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1186/s13073-020-00772-z)

[9. (Coburn1997Smooth) Ronald F. Coburn, Edward F. Labelle, Thomas Griffiths, and Carl B. Baron. Smooth muscle sarcolemma-associated phospholipase c-β2; agonist-evoked translocation. Journal of Cellular Physiology, 171(3):271–283, June 1997. URL: http://dx.doi.org/10.1002/(SICI)1097-4652(199706)171:3<271::AID-JCP5>3.0.CO;2-L, doi:10.1002/(sici)1097-4652(199706)171:3<271::aid-jcp5>3.0.co;2-l. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/(SICI)1097-4652(199706)171:3)

[10. (Lo2014Neuropeptide) V. R. Lo Vasco, M. Leopizzi, C. Puggioni, C. Della Rocca, and R. Businaro. Neuropeptide y reduces the expression of plcb2, plcd1 and selected plc genes in cultured human endothelial cells. Molecular and Cellular Biochemistry, 394(1–2):43–52, June 2014. URL: http://dx.doi.org/10.1007/s11010-014-2079-2, doi:10.1007/s11010-014-2079-2. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s11010-014-2079-2)